UK Medicines Information
FDA warns of increased risk of death with febuxostat (Uloric)
Information type:
Safety alerts
Source:
US Food and Drug Administration
Specialities:
Cardiovascular system disorders | Musculo-skeletal disorders
Summary
Following review of a safety clinical trial that found an increased risk of cardiac mortality and all-cause mortality, the FDA is advising health care professionals to reserve febuxostat for use only in patients who have failed or do not tolerate allopurinol.
UKMi comment
The Uloric brand of febuxostat is not licensed in the UK.
Related links: